Seikagaku (4548) · InitiativeRestated
Exclusive Development and Sales License for SI-6603 Worldwide Except Japan
First written in FY2017-Q2. 1 of 2 entries say "Restated". Latest entry: FY2017.
2entries
2years
0from disclosures
How it moved
Same theme, other companies
Grant of exclusive development and commercialization rights for SI-6603 outside Japan to FerringA theme 1 companies write about · 0 as a headwind · 1 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- FY2017RestatedAnnual report
「In August 2016, we also entered into a licensing agreement with Ferring Pharmaceuticals, headquartered in Switzerland, for the exclusive development and sales of SI-6603 worldwide excluding Japan.」
The exclusive development and sales licensing agreement with Ferring for SI-6603 worldwide excluding Japan continues to be disclosed. - FY2017-Q2First statedAnnual report
「Exclusive development and sales rights for SI-6603, a treatment for lumbar disc herniation, worldwide excluding Japan. Contract term: From the contract date until the later of the expiration date of the applicable patents or the date 15 years after the product launch date, with renewal every 3 years thereafter」
In August 2016, we entered into an agreement with Ferring International Center S.A. granting exclusive development and sales rights for SI-6603 worldwide excluding Japan.